Silexion reports positive early data for SIL204 pancreatic cancer immunotherapy

Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read

Key Changes

• high

  Company announced positive preliminary immunotherapy findings for SIL204, its drug candidate targeting KRAS-driven pancreatic cancer, marking a clinical development milestone for the program.

  Item 7.01 Press Release verify on EDGAR →
• medium

  The 8-K filing provides only the press release title without detailed clinical data, efficacy metrics, or patient outcomes from the study.

  Exhibit 99.1 verify on EDGAR →